Trial Profile
A Study to Evaluate the Effects of MK-4305 in Patients With Obstructive Sleep Apnea
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Sleep apnoea syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 15 Aug 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
- 30 Sep 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
- 30 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.